Thursday, December 29, 2022 11:39:53 AM
The test-to-enter is simply theatrics at this point. There is so much Covid everywhere right now, so many new variants cropping all over. Bizarre we aren’t doing things we know works (masks, ventilation, boosting), & now are back to square 1 with ineffective antics.
https://twitter.com/oni_blackstock/status/1608479481601363968?s=20&t=wnVZlmX1wivPfDe8H8Jiww
ps. And should add Better Theraputics like Bucillamine, we know it should work much better than Nac! already....
The test-to-enter is simply theatrics at this point. There is so much Covid everywhere right now, so many new variants cropping all over. Bizarre we aren’t doing things we know works (masks, ventilation, boosting), & now are back to square 1 with ineffective antics. https://t.co/VaWJQ4C7s5
— Sabina Vohra-Miller (@SabiVM) December 29, 2022
https://twitter.com/oni_blackstock/status/1608479481601363968?s=20&t=wnVZlmX1wivPfDe8H8Jiww
ps. And should add Better Theraputics like Bucillamine, we know it should work much better than Nac! already....
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
